

1 Title:

2 **Knowledge, uptake and intention to use antibiotic post-exposure prophylaxis and**
3 **meningococcal B vaccine (4CMenB) for gonorrhoea among a large, online community sample of**
4 **gay, bisexual and other men who have sex with men in the UK**

5 Authors:

6 Dana Ogaz (dana.ogaz@ukhsa.gov.uk, ORCID ID: 0000-0002-1900-8892) ^{1,2}
7 Jessica Edney (jessica.edney@ukhsa.gov.uk, ORCID ID: 0009-0003-9920-1848) ¹
8 Dawn Phillips (dawn.phillips@ukhsa.gov.uk, ORCID ID: 0009-0001-1508-1697) ¹
9 Dolores Mullen (dolores.mullen@ukhsa.gov.uk, ORCID ID: 0009-0006-1741-1449) ¹
10 David Reid (david.reid@ucl.ac.uk, ORCID ID: 0000-0001-6832-2418) ^{2,3}
11 Ruth Wilkie (ruth.wilkie@wales.nhs.uk, ORCID ID: 0009-0000-9568-1862) ¹
12 Erna Buitendam (erna.buitendam@ukhsa.gov.uk, ORCID ID: 0000-0002-4612-7408) ¹
13 James Bell (james.bell@ukhsa.gov.uk, ORCID ID: 0000-0002-2265-1205) ^{1,2}
14 Catherine M Lowndes (kathy.lowndes@ukhsa.gov.uk, ORCID ID: 0009-0000-9171-9149) ¹
15 Gwenda Hughes (gwenda.hughes@lshtm.ac.uk, ORCID ID: 0000-0003-2090-7702) ⁴
16 Helen Fifer (helen.fifer@ukhsa.gov.uk, ORCID ID 0000-0001-7756-403X) ¹
17 Catherine H Mercer (c.mercer@ucl.ac.uk, ORCID ID: 0000-0002-4220-5034) ^{2,3}
18 John Saunders (john.saunders@uksa.gov.uk, ORCID ID: 0000-0003-3020-9916) ^{1,2}
19 Hamish Mohammed (hamish.mohammed@ukhsa.gov.uk, ORCID ID: 0000-0002-2060-7286) ^{1,2}

20 Affiliations: ¹ Blood Safety, Hepatitis, STI & HIV Division, UK Health Security Agency, London,
21 United Kingdom ² The National Institute for Health Research Health Protection Research Unit in
22 Blood Borne and Sexually Transmitted Infections at University College London in partnership with
23 the UK Health Security Agency, London, United Kingdom ³ Institute for Global Health, University
24 College London, London, United Kingdom ⁴ UK Public Health Rapid Support Team, London School
25 of Hygiene & Tropical Medicine, London, United Kingdom

26

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

27 Corresponding author:

28 Dana Ogaz (dana.ogaz@ukhsa.gov.uk)

29 UK Health Security Agency, 61 Colindale Ave, London, UK, NW9 5EQ

30 Abstract:

31 **Introduction:** Novel STI prevention interventions, including doxycycline post-exposure prophylaxis
32 (doxyPEP) and meningococcal B vaccination (4CMenB) against gonorrhoea, have been increasingly
33 examined as tools to aid STI control. There is emerging evidence of the efficacy of doxyPEP in
34 preventing bacterial STIs; however limited data exist on the extent of use in the UK. We examined
35 self-reported knowledge and use of antibiotic post-exposure prophylaxis (PEP), and intention to use
36 (ITU) doxyPEP and 4CMenB among a large, community sample of gay, bisexual and other men who
37 have sex with men (GBMSM) in the UK.

38 **Methods:** Using data collected by the RiISH survey (November/December 2023), part of a series of
39 online surveys of GBMSM in the UK, we describe (% , [95% CI]) self-reported knowledge and use of
40 antibiotic PEP (including doxyPEP) and doxyPEP and 4CMenB ITU. Using bivariate and
41 multivariable logistic regression, we examined correlates of ever using antibiotic PEP, doxyPEP ITU,
42 and 4CMenB ITU, respectively, adjusting for sociodemographic characteristics and a composite
43 marker of sexual risk defined as reporting (in the last three months): ≥ 5 condomless anal sex partners,
44 bacterial STI diagnosis, chemsex, and/or meeting partners at sex-on-premises venues, sex parties, or
45 cruising locations.

46 **Results:** Of 1,106 participants (median age: 44 years [IQR: 34-54]), 34% (30%-37%) knew of
47 antibiotic PEP; 8% (6%-10%) ever reported antibiotic PEP use. Among those who did, most reported
48 use in the last year (84%, 73/87) and exclusively used doxycycline (69%, 60/87). Over half of
49 participants reported doxyPEP ITU (51% [47%-56%]) while over two-thirds (64% [60%-69%])
50 reported 4CMenB ITU. GBMSM with markers of sexual risk and with uptake of other preventative
51 interventions were more likely to report ever using antibiotic PEP as well as doxyPEP and 4CMenB
52 ITU, respectively. HIV-PrEP users and people living with HIV (PLWHIV) were more likely to report
53 STI prophylaxis use and ITU than HIV-negative GBMSM not reporting recent HIV-PrEP use.

54 **Discussion:** There were high levels of intended use of novel STI prevention interventions. Fewer than
55 one in ten GBMSM had reported ever using antibiotic PEP, with usage more common among those at
56 greater risk of STIs. Future guidelines and health promotion for 4CMenB and antibiotic PEP must be
57 carefully crafted alongside clinical experts and community partners, given intervention complexity
58 and the risk of presenting conflicting public health messages regarding antimicrobial stewardship.

59 Introduction

60 There have been continued and unprecedented increases in bacterial sexually transmitted infections
61 (STIs) (e.g., chlamydia, gonorrhoea, syphilis) among gay, bisexual, and other men who have sex with
62 men (GBMSM) in the UK since the early 2000s (1, 2). There has been sustained progress towards
63 HIV elimination through combination prevention interventions, including HIV-PrEP, HIV testing, and
64 Treatment as Prevention (TasP) (3), but controlling transmission of other STIs remains challenging.
65 Novel STI prevention interventions have been increasingly considered to aid STI control in key
66 populations but advocacy for the use of biomedical interventions, including antibiotic prophylaxis and
67 meningococcal B vaccination (4CMenB) for GBMSM, has been mixed. Concerns with widespread
68 implementation include the potential effects on antimicrobial resistance (AMR) selection as well as
69 individual sexual risk perception and resultant behavioural risk compensation (4-6). In the UK,
70 elimination of the 2022 mpox outbreak was jointly achieved with co-produced community messaging
71 and individual-level behavioural change, alongside a targeted vaccination programme. This
72 underlined the importance of a community supported response (7) and rapid deployment interventions
73 as part of a cadre of combination prevention tools (8). However, similar approaches for bacterial STI
74 control have been less effective (9), which highlights a need to consider new and novel prevention
75 interventions as part of modern control measures.

76 The use of self-sourced antibiotics as pre- and post-exposure prophylaxis for STI prevention has been
77 reported in UK GBMSM from as early as 2019 (10, 11), with uptake estimates of 3.6% across a
78 community sample of GBMSM in 2020/2021 (12). Recent studies have shown a reduction in bacterial
79 STI incidence in GBMSM using doxycycline post-exposure prophylaxis (doxyPEP) (13-17), and a
80 guideline for doxyPEP use in the UK is under development.

81 Observational studies of 4CMenB vaccination for *Neisseria meningitidis* serogroup B bacteria have
82 shown cross-protection against *Neisseria gonorrhoeae* (gonorrhoea) (18). Modelling suggests
83 vaccination for GBMSM at risk can be a cost-effective strategy with significant impact on gonorrhoea
84 incidence, while also conferring community-level benefits that could curb incidence, even within
85 conservative efficacy estimates (19). Real-world effectiveness of 4CMenB has shown a reduction in
86 gonorrhoea incidence of between 22%-47% (14, 20-23). More recently, recommendations of a
87 gonorrhoea vaccination programme using 4CMenB vaccine, primarily (not exclusively) targeting
88 GBMSM, have been made by the UK's Joint Committee on Vaccination and Immunisation (JCVI)
89 (24).

90 At the time of writing this article, doxyPEP and 4CMenB vaccination are not yet recommended for
91 STI prevention in the UK. However, in preparation for potential use of these novel STI interventions
92 across SHS, we explored data from the most recent round of a serial, cross-sectional survey of
93 GBMSM in the UK to examine self-reported knowledge, uptake, and regimens used as antibiotic

94 post-exposure prophylaxis (PEP) for STI prevention. To gauge community interest in these novel STI
95 preventative interventions, we also explored the intention to use doxyPEP and 4CMenB assuming
96 availability, efficacy, and recommendation in the UK.

97 **Methods**

98 **Study population and data collection**

99 We used data collected from the most recent round (November/December 2023) of the ‘Reducing
100 inequalities in Sexual Health’ (RiiSH) surveys: a series of cross-sectional surveys examining the
101 sexual health and well-being of a community sample of GBMSM in the UK. Methods for RiiSH 2023
102 were adapted from previous study rounds (25, 26). Stakeholder engagement with UK community
103 groups prior to implementation was undertaken to review core questions and inform question
104 additions for the 2023 round.

105 Participants were recruited from 7th November-6th December 2023 through social networking sites
106 (Facebook, Instagram, X) and a geospatial dating application (Grindr). An additional survey link was
107 created for dissemination by voluntary and community networks which was cascaded via social
108 networking sites (hereafter, community-cascaded link). Due to survey hosting limitations, online
109 click-throughs were not captured.

110 GBMSM included in analyses were self-identifying men (cisgender/transgender), transgender women,
111 or gender-diverse individuals assigned male at birth (AMAB), aged ≥ 16 years, resident in the UK and
112 reporting sex with a man in the last year. We obtained online consent and there was no incentive to
113 participate.

114 Data was collected using the Snap Surveys platform (www.snapsurveys.com). Data management and
115 analysis was conducted using Stata 17.0 (StataCorp LLC). Ethical approval for this study was granted
116 by the UKHSA Research and Ethics Governance Group (REGG; ref: R&D 524).

117 **Knowledge and use of antibiotics after sex for STI prevention**

118 We calculated the percentage (%) and 95% confidence intervals (95% CI) of GBMSM having ever
119 heard of using antibiotic PEP (‘Before taking this survey, had you heard about using antibiotics
120 immediately after sex to prevent STIs other than HIV [e.g., doxy PEP]?’) and those that reported use
121 (‘Have you ever used antibiotics in this way?’).

122 Among those reporting the use of antibiotic PEP, we examined recency of use (‘When did you last
123 use antibiotics in this way?’) and antibiotics ever used. In those who had never used STI prophylaxis,
124 we calculated (% , 95% CI) those who had considered use (‘Have you ever considered taking
125 antibiotics in this way?’) (see Appendix I for questions).

126 Correlates of ever using antibiotic post-exposure prophylaxis (PEP) for STI
127 prevention

128 Using bivariate and multivariable logistic regression, we examined correlates of ever using antibiotic
129 PEP, adjusting for sociodemographic characteristics with evidence of association to our outcome and
130 a composite marker of sexual risk defined as reporting (in the last three months): ≥ 5 condomless anal
131 sex partners, bacterial STI diagnosis, chemsex, and/or meeting partners at sex-on-premises venues,
132 sex parties, or cruising locations, to minimise collinearity in adjusted models. This composite was
133 based on previously described predictors of STI prophylaxis use (10, 12).

134 Correlates examined included markers of sexual risk (behavioural characteristics, sexual partnerships
135 in the last three months), clinical characteristics (HIV status and PrEP use), SHS use in the last year,
136 well-being, and sexual satisfaction indicators. We used mental health and personal well-being
137 indicators derived from the UK ONS that were dichotomised, as per ONS harmonisation standards
138 (27), for measures of low life satisfaction, low life worthwhileness, low happiness, and high anxiety.
139 Agreement (agree/strongly agree) with the statement, ‘I feel satisfied with my sex life’ was used as a
140 measure of sexual satisfaction and based on framing used in the National Surveys of Sexual Attitudes
141 and Lifestyles (Natsal) (28). In regression analyses, all p-values less than 5% were considered as
142 evidence of association (i.e., statistically significant).

143 Correlates of self-reported intention to use doxycycline post-exposure prophylaxis
144 (doxyPEP) and 4CMenB

145 All participants were asked about their likelihood (‘Very unlikely’, ‘Somewhat unlikely’, ‘Somewhat
146 likely’, ‘Very likely’, ‘I don’t know’) of doxyPEP uptake, if available and considered safe and
147 effective, and about their likelihood of 4CMenB uptake (referred to as Bexsero in survey questions), if
148 available and with 30-50% effectiveness against gonorrhoea (see Appendix I for questions).

149 We initially aimed to use ordinal logistic regression to assess correlates of ordinal uptake outcomes;
150 However, given heavy skew to the highest positive responses for each intervention, outcome measures
151 were dichotomised (‘Very likely’ vs all else), where intention to use (ITU) was defined as those ‘very
152 likely’ to consider intervention uptake. As per methodology above, we examined correlates of
153 doxyPEP and 4CMenB ITU respectively, using bivariate and multivariable logistic regression.

154 Results

155 There were 1,322 GBMSM who completed the RiiSH 2023 survey, of whom, 1,106 met participation
156 criteria and were included in analyses (Appendix II). Half of all participants were recruited from
157 Grindr (50%), followed by Instagram (23%), Facebook (19%), and community-cascaded links (7%).

158 Participants primarily resided in England (85% 941/1,106), were of White ethnicity (89% 984/1,106),
159 and were UK-born (78% 860/1,106). The median age of participants was 44 years (interquartile
160 range: 34-54), with two-thirds reporting degree-level education (62% 691/1,106). Over three-quarters

161 of participants were employed (78% 868/1,106), while less than half (41% 454/1,106) reported being
162 financially comfortable.

163 In the lookback period (i.e., since August 2023), one in five participants had ≥ 5 male condomless anal
164 sex (CAS) partners (21% 231/1,106) and 8.7% (96/1,106) reported at least one positive bacterial STI
165 test. Additional characteristics are described in Table 1.

166 Knowledge and use of antibiotic post-exposure prophylaxis (PEP) for STI prevention
167 Over a third (34%, 95% CI: 34%-37% 373/1,106) of all participants had ever heard about using
168 antibiotics after sex for STI prevention; 8% (95% CI: 6%-10% 87/1,106) reported ever having used
169 antibiotic PEP (Figure 1). Among the latter, 84% (73/87) had done so in the last year, where most
170 reported ever using doxycycline (80%, 68/87) and 69% (60/87) specified its exclusive use. One in ten
171 participants were uncertain of which antibiotics they had used previously (11% 10/87), and few
172 reported exclusive azithromycin (2% 2/87) or amoxicillin use (8% 8/87) (Appendix III). In the two-
173 thirds (65% 717/1,106) of GBMSM who had never used antibiotic PEPs, nearly one in five (18% 95%
174 CI: 16%-21% 186/1,019) had ever considered use.

175 Factors associated with ever using antibiotic post-exposure prophylaxis (PEP) for STI
176 prevention

177 GBMSM with lower education levels (aOR: 0.58 [0.34-0.97] below degree-level vs degree-level)
178 were less likely to report use, while those born outside the UK (aOR: 1.65 [1.01-2.70]), and those
179 reporting or considering other preventative interventions (e.g., mpox vaccination), were more likely to
180 report STI prophylaxis use. HIV-PrEP users and people living with HIV (PLWHIV) were more likely
181 to report STI prophylaxis use than HIV-negative GBMSM not reporting recent HIV-PrEP use (Table
182 2).

183 Correlates of intention to use doxycycline post-exposure prophylaxis (dPEP ITU)

184 Among all participants, 51% (95% CI: 47%-56%, 568/1,106) reported doxyPEP ITU, reaching 68%
185 (95% CI: 60%-69%, 487/713) among those with markers of sexual risk in the last three months. In
186 bivariate analyses, no other sociodemographic characteristics apart from age-group were associated
187 with doxyPEP ITU. Individual markers of sexual risk (comprising our composite measure) were
188 positively associated with doxyPEP ITU (Table 3).

189 In age-adjusted models, positive associations between doxyPEP ITU and HIV status and recent PrEP
190 use remained. Compared to HIV-negative GBMSM without recent PrEP use (in last three months),
191 PLWHIV (aOR 1.74 [1.28-2.57]) and HIV-negative recent PrEP users (aOR 1.40 [1.17-1.84])
192 reported doxyPEP ITU. GBMSM who had an SHS visit in the last year were more likely to report
193 doxyPEP ITU (aOR: 1.66 [1.29-2.14]) while those reporting high anxiety were less likely (aOR 0.77
194 [0.80-0.99]). 4CMenB ITU was highly correlated with doxyPEP ITU (aOR 8.93 [6.63-12.1]).

195 GBMSM with markers of sexual risk in the last three months were more likely to report doxyPEP ITU
196 (aOR 1.50 [1.16-1.94]). While we found no association with age in adjusted models, there were
197 indications of decreased doxyPEP ITU in younger age-groups (aOR 0.71 [0.49-1.03] aged 16-29 vs
198 ≥ 45 years).

199 Correlates of intention to use 4CMenB (4CMenB ITU)

200 Over two-thirds of all participants (64%, 713/1,106) reported 4CMenB ITU, increasing to 75%
201 (270/361) among those with markers of sexual risk in the last three months. In bivariate analyses, age-
202 group, sexual orientation, employment status, HIV status and PrEP use, along with most individual
203 markers of sexual risk, were associated with 4CMenB ITU (Table 4).

204 In models adjusted for associated sociodemographic characteristics and our composite marker of
205 sexual risk, PLWHIV and recent HIV-negative PrEP users were about twice as likely to report
206 4CMenB ITU compared to HIV-negative GBMSM not reporting recent HIV-PrEP use. Sexual health
207 service use in the last year (aOR 2.45 [1.87-3.21]) and uptake of preventative interventions (e.g.
208 mpox vaccination) were positively associated with 4CMenB ITU, and there was high correlation with
209 doxyPEP ITU (aOR 10.1 [7.33-13.8]).

210 Younger GBMSM were more likely to report 4CMenB ITU (aOR 2.16 [1.44-3.25] aged 16-29 vs ≥ 45
211 years), while bisexual-identifying (aOR 0.62 [0.45-0.86]) and those with lower educational
212 qualifications (aOR 0.57 [0.44-0.73]) were less likely to report 4CMenB ITU. GBMSM with
213 composite markers of sexual risk were twice as likely to report ITU (aOR 2.09 [1.56-2.79]).

214 Discussion

215 We show that the majority of GBMSM in our community sample would choose to access to doxyPEP
216 and the 4CMenB vaccine were they available and recommended for use in the UK, and that intention
217 to use is greater in those potentially most likely to benefit. Over half of participants (51%) expressed
218 an intention use doxyPEP, with even greater levels (64%) reporting intention to use 4CMenB. While
219 findings demonstrate substantial interest in the use of doxyPEP, fewer than one in ten (8%) GBMSM
220 who responded to this survey reported use of antibiotic PEP, with usage more common among those
221 at greater risk of STIs. These findings, however, are based on small absolute numbers, but update
222 previous estimates of the extent of antibiotic PEP use in GBMSM prior to the publication of the first
223 UK guidelines.

224 Among those using antibiotic PEP, most reported use of appropriate, evidence-based antibiotics for
225 use as post-exposure STI prophylaxis (i.e., doxycycline). However, there were indications of
226 unknown and inappropriate antibiotic use, which is concerning given this may drive AMR as well as
227 cause individual harm, possibly to a greater extent than doxyPEP use. Over a third of all participants

228 reported knowledge of antibiotic PEP for STI prevention, and while few reported uptake, one in five
229 of GBMSM who had not reported use had ever considered taking antibiotics to prevent STIs.

230 Consistent with previous studies (10-12), we found higher uptake of STI prophylaxis in PLWHIV
231 (15%), HIV-PrEP users (12%), and GBMSM at greater risk of STIs as indicated by recent markers of
232 sexual risk (14%). GBMSM with lower levels of education were less likely to report antibiotic PEP
233 use, while prior mpox vaccination uptake was positively associated with use. Compared with a recent
234 study in Germany which estimate doxyPEP uptake in around 20% of GBMSM (29), our sample
235 estimates were lower but this may reflect the wider availability of STI testing in the UK (30, 31).
236 Given the current evidence base, we framed uptake of prophylactic antibiotics around post-exposure
237 use. Questions across behavioural surveys, including prior RiiSH rounds, have included questions
238 about both pre- and post-exposure use. This may limit comparisons with estimates in previous
239 literature and underestimate overall use of STI prophylaxis as STI prevention. Future research,
240 monitoring and evaluation would benefit from a consistent definition, which will itself be facilitated
241 by the upcoming national UK guidelines.

242 Over half of participants indicated doxyPEP ITU. While there was a high correlation between
243 doxyPEP and 4CMenB ITU, a higher proportion of GBMSM - approximately two-thirds - reported
244 4CMenB ITU. AMR concerns, consistently highlighted in contemporary health settings as part of
245 antimicrobial stewardship initiatives (32), could explain lower doxyPEP ITU. Those reporting high
246 anxiety were less likely to report doxyPEP ITU, which may signal hesitancy arising from AMR
247 worries and reluctance to use antibiotics prophylactically. Similar views were found in a qualitative
248 study of SHS attendees, where there was greater acceptability and support of vaccinations for STI
249 prevention as alternatives to antibiotic prophylaxis use (33). We found levels of 4CMenB ITU were
250 similar to the high self-reported uptake of opportunistically offered Hepatitis A, Hepatitis B and
251 human papillomavirus (HPV) vaccination in SHS among a community sample of GBMSM (34),
252 which may influence greater 4CMenB uptake acceptability.

253 As with STI prophylaxis uptake, PLWHIV, recent HIV-PrEP users, those accessing SHS, and those at
254 greater sexual risk were more likely to report 4CMenB ITU. However, we also found further
255 associations with age and sexual orientation. Younger age-groups were more likely to report 4CMenB
256 ITU, which may present opportunities for further prevention intervention education and uptake in
257 groups with known STI outcome inequalities (35). Like recent vaccination uptake examinations in
258 GBMSM (34, 36), we found differences by socioeconomic characteristics, with lower 4CMenB ITU
259 in those reporting educational qualifications below degree-level; as well as lower ITU among sexual
260 minorities (i.e., bisexual and straight-identifying GBMSM). Inclusive and accessible health promotion
261 and patient education surrounding novel STI prevention interventions, especially considering self-

262 sourcing of antibiotics, will be imperative to minimise knowledge and uptake inequalities and to
263 clearly inform risks in balance of benefits to STI prophylaxis use.

264 Limitations

265 This cross-sectional study is subject to limitations. Our sample population likely experiences higher
266 levels of sexual risk relative to the wider population of GBMSM in the UK (37, 38). We aimed to
267 recruit from a broader spectrum of GBMSM who likely have differing sexual risk relative to clinic
268 recruited samples. ITU measures may not equate to uptake in practice but help gauge interest and
269 acceptability among GBMSM who would likely comprise targeted groups for these interventions.
270 Dichotomising outcome measures limits interpretation and could have led to conservative ITU
271 estimates. While we posited that sexual satisfaction could be influenced by actual or intended uptake
272 of STI prevention interventions, we found no evidence of association, though larger studies are
273 needed to examine the role of uptake on more holistic measures of sexual satisfaction and well-being.
274 We collected no personal identifiers to facilitate the reporting of sensitive data on sexual behaviours;
275 however, survey responses may be subject to social acceptability bias. Sample selection could be
276 subject to digital exclusion, and we do not know how representative our study sample is of GBMSM
277 using social networking and dating applications. However, consistent methodology and community-
278 partnered implementation are strengths of this long-running survey series and consistently aid the
279 characterisation of behavioural risk, currently absent from available national STI surveillance, as well
280 as actual and intended preventative intervention uptake among key populations in the UK.

281 Implications

282 Findings from this study illustrate a community sample of GBMSM with considerable interest in the
283 use of novel biomedical STI interventions, which is not dissimilar to the high uptake seen of HIV-
284 PrEP and other STI and viral hepatitis vaccination in UK GBMSM. As seen in the PrEP Impact Trial,
285 an implementation trial assessing HIV-PrEP eligibility and uptake in the UK from 2017-2020 (39),
286 eligibility for trial places quickly outstripped availability at the onset of the trial (10,000, increasing to
287 26,000), largely attributable to early knowledge and engagement facilitated by community
288 organisations (40, 41). A significant proportion of our community sample indicated likely uptake of
289 these preventative interventions with high correlation of ITU for both, signalling the benefit of shared
290 education and offer of prevention interventions within SHS or outreach settings. GBMSM at greater
291 risk of STIs were more likely to report ever using STI prophylaxis as well as doxyPEP and 4CMenB
292 ITU, suggesting an appropriate assessment of personal sexual risk, however, we did find potential
293 sociodemographic and SHS engagement-based uptake differences common in uptake of other
294 preventative interventions such as mpox vaccination and HIV-PrEP. While there is no
295 recommendation for the use of doxyPEP as STI prevention in the UK at the time of writing, there are
296 early indications of knowledge of antibiotic PEP, as well as uptake among GBMSM through private
297 or off-license purchasing. Community-led knowledge mobilisation efforts (42) have likely boosted

298 awareness of evidence-based uptake regimens associated with STI incidence declines in GBMSM,
299 now recommended in some US cities (43). At present, the upcoming UK doxyPEP guidelines will
300 likely influence the decision of implementation across SHS. Also, the JCVI recommendation for a
301 targeted opportunistic gonorrhoea vaccination programme using 4CMenB is awaiting approval by
302 health ministers in the UK.

303 Conclusion

304 While regular testing, condom promotion, and treatment as prevention remain an integral foundation
305 to STI prevention in the UK, these approaches have not curbed rapid increases in STI diagnoses
306 among GBMSM and other key populations in the last decade. Novel prevention interventions should
307 be considered to supplement existing control strategies. As adoption of doxyPEP, 4CMenB
308 vaccination and other interventions across SHS is considered in the UK, future guidelines and health
309 promotion messaging must be carefully crafted alongside clinical experts and community partners
310 given intervention complexity, implications to sexual behaviour and AMR selection, and the risk of
311 presenting conflicting public health messages regarding antibiotic stewardship. Robust monitoring
312 and evaluation will be crucial to understand the impact of doxyPEP and 4CMenB use on AMR and
313 STI incidence in key populations if rolled out across SHS. Given lessons learned from the
314 implementation of HIV prevention interventions, the magnitude of community interest and uptake
315 must not be underestimated and there will be a need to ensure equitable access to these interventions
316 to those in greatest need (24). There will be a similar need for equity considerations in health
317 promotion, patient education and uptake across different service models, including those delivered
318 primarily online, depending on local need. Minimising knowledge and potential accessibility barriers
319 for those who may benefit from future STI preventative interventions must be considered from the
320 outset of planning and embedded in implementation and monitoring to limit health inequalities and to
321 facilitate empowered decision-making that benefits individual-level sexual wellbeing and autonomy.

322 Acknowledgements:

323 We thank Elizabeth Fearon (University College London), Takudzwa Mukiwa (Terrence Higgins
324 Trust), Will Nutland (The Love Tank) and Benjamin Weil (The Love Tank) for their review and
325 contributions to the RiiSH 2023 survey. We thank Emmanuel Musah for review of our draft
326 manuscript.

327 We acknowledge members of the National Institute for Health and Care Research Health Protection
328 Research Unit (NIHR HPRU) in Blood Borne and Sexually Transmitted Infections (BBSTI) Steering
329 Committee: Caroline Sabin, John Saunders, Catherine H. Mercer, Hamish Mohammed (previously
330 Gwenda Hughes), Greta Rait, Ruth Simmons, William Rosenberg, Tamyo Mbisa, Rosalind Raine,
331 Sema Mandal, Rosamund Yu, Samreen Ijaz, Fabiana Lorencatto, Rachel Hunter, Kirsty Foster and
332 Mamooma Tahir.

333 Data availability statement:

334 The data that support the findings of this study are available upon reasonable request from the UK
335 Health Security Agency (UKHSA). Requests can be directed to Dr Hamish Mohammed
336 (riish_survey@ukhsa.gov.uk).

337 Keywords:

338 STI prevention, GBMSM, doxyPEP, Bexsero, 4CMenB, meningococcal B vaccine, vaccination,
339 antibiotics, UK

340 Funding:

341 This study did not receive any funding; however, David Reid and Catherine H Mercer were funded as
342 part of The National Institute for Health Research Health Protection Research Unit in Blood Borne
343 and Sexually Transmitted Infections at University College London in partnership with the UK Health
344 Security Agency.

345 Ethical approval:

346 Young people aged 16-17 years were eligible to participate in this survey as this group represent a key
347 population at risk of STI acquisition in the UK and are important to include in this research. Parental
348 consent of participants aged 18 or younger was not sought. Ethical guidelines produced by the British
349 Psychological Society and General Medical Council suggest consent from parents should be sought
350 for those under age 16 and that those aged 16 and over may be presumed to be able to reach informed
351 consent if the information on the study, and the way that data is collected, stored, and used is clear
352 (1,2). This information is included for all potential participants at the beginning of the survey. Ethical
353 approval of this study was provided by the UKHSA Research and Ethics Governance Group (REGG;
354 ref: R&D 524). Online informed consent was received from all participants and all methods were
355 performed in accordance with guidelines and regulations set by the UKHSA REGG.

- 356 1. Oates, J., Carpenter, D., Fisher, M., Goodson, S., Hannah, B., Kwiatkowski, R., Prutton, K.,
357 Reeves, D., & Wainwright, T. (2021). BPS code of human research ethics
358 2. General Medical Council. (2018). 0-18 years: guidance for all doctors. Making Decisions –
359 Assessing the capacity to consent.

360 Competing interests:

361 Authors have no competing interests to declare.

362

363

364 References

- 365 1. Mighelsen S, Enayat Q, Harb A, Daahir U, Slater L, Anderson A, et al. Sexually transmitted
366 infections and screening for chlamydia in England, 2022: UK Health Security Agency, London; 2023
367 [Available from: [https://www.gov.uk/government/statistics/sexually-transmitted-infections-stis-](https://www.gov.uk/government/statistics/sexually-transmitted-infections-stis-annual-data-tables/sexually-transmitted-infections-and-screening-for-chlamydia-in-england-2022-report)
368 [annual-data-tables/sexually-transmitted-infections-and-screening-for-chlamydia-in-england-2022-](https://www.gov.uk/government/statistics/sexually-transmitted-infections-and-screening-for-chlamydia-in-england-2022-report)
369 [report](https://www.gov.uk/government/statistics/sexually-transmitted-infections-and-screening-for-chlamydia-in-england-2022-report).
- 370 2. Mohammed H, Blomquist P, Ogaz D, Duffell S, Furegato M, Checchi M, et al. 100 years of
371 STIs in the UK: a review of national surveillance data. *Sex Transm Infect.* 2018;94(8):553-8.
- 372 3. Brown AE, Nash S, Connor N, Kirwan PD, Ogaz D, Croxford S, et al. Towards elimination of
373 HIV transmission, AIDS and HIV-related deaths in the UK. *HIV Med.* 2018.
- 374 4. Kong FYS, Kenyon C, Unemo M. Important considerations regarding the widespread use of
375 doxycycline chemoprophylaxis against sexually transmitted infections. *J Antimicrob Chemother.*
376 2023;78(7):1561-8.
- 377 5. Grant JS, Stafylis C, Celum C, Grennan T, Haire B, Kaldor J, et al. Doxycycline Prophylaxis for
378 Bacterial Sexually Transmitted Infections. *Clin Infect Dis.* 2020;70(6):1247-53.
- 379 6. Traeger MW, Mayer KH, Krakower DS, Gitin S, Jenness SM, Marcus JL. Potential impact of
380 doxycycline post-exposure prophylaxis prescribing strategies on incidence of bacterial sexually
381 transmitted infections. *Clin Infect Dis.* 2023.
- 382 7. UK Health Security Agency. Mpox and sexual health: outreach and engagement fund 2022
383 [cited 2024 10 May]. Available from: [https://www.gov.uk/government/publications/mpox-and-](https://www.gov.uk/government/publications/mpox-and-sexual-health-outreach-and-engagement-fund)
384 [sexual-health-outreach-and-engagement-fund](https://www.gov.uk/government/publications/mpox-and-sexual-health-outreach-and-engagement-fund).
- 385 8. Zhang X-S, Mandal S, Mohammed H, Turner C, Florence I, Walker J, et al. Transmission
386 dynamics and effect of control measures on the 2022 outbreak of mpox among gay, bisexual, and
387 other men who have sex with men in England: a mathematical modelling study. *The Lancet*
388 *Infectious Diseases.* 2024;24(1):65-74.
- 389 9. Kenyon C, Herrmann B, Hughes G, de Vries HJC. Management of asymptomatic sexually
390 transmitted infections in Europe: towards a differentiated, evidence-based approach. *The Lancet*
391 *Regional Health - Europe.* 2023;34:100743.
- 392 10. O'Halloran C, Croxford S, Mohammed H, Gill ON, Hughes G, Fifer H, et al. Factors associated
393 with reporting antibiotic use as STI prophylaxis among HIV PrEP users: findings from a cross-sectional
394 online community survey, May-July 2019, UK. *Sex Transm Infect.* 2021;97(6):429-33.
- 395 11. Ogaz D, Logan L, Curtis TJ, McDonagh L, Guerra L, Bradshaw D, et al. PrEP use and unmet
396 PrEP-need among men who have sex with men in London prior to the implementation of a national
397 PrEP programme, a cross-sectional study from June to August 2019. *BMC Public Health.*
398 2022;22(1):1105.
- 399 12. Kohli M, Reid D, Pulford CV, Howarth A, Brown J, Mohammed H, et al. Choice of antibiotics
400 for prophylaxis of bacterial STIs among individuals currently self-sourcing. *Sex Transm Infect.*
401 2022;98(2):158.
- 402 13. Molina JM, Charreau I, Chidiac C, Pialoux G, Cua E, Delaugerre C, et al. Post-exposure
403 prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with
404 men: an open-label randomised substudy of the ANRS IPERGAY trial. *Lancet Infect Dis.*
405 2018;18(3):308-17.
- 406 14. Molina JM, Berçot B, Assoumou L, Algarte-Genin M, Rubenstein E, Pialoux G, et al. Final
407 Results of ANRS 174 DOXYVAC: A Randomized trial to Prevent STIs in MSM on PrEP Conference on
408 Retroviruses and Opportunistic Infections, Denver, Colorado2024 [updated 2024 March; cited 2024
409 01 May]. Available from: [https://www.croiconference.org/abstract/final-results-of-anrs-174-](https://www.croiconference.org/abstract/final-results-of-anrs-174-doxyvac-a-randomized-trial-to-prevent-sti-in-msm-on-prep/)
410 [doxyvac-a-randomized-trial-to-prevent-sti-in-msm-on-prep/](https://www.croiconference.org/abstract/final-results-of-anrs-174-doxyvac-a-randomized-trial-to-prevent-sti-in-msm-on-prep/).
- 411 15. Luetkemeyer AF, Donnell D, Dombrowski JC, Cohen S, Grabow C, Brown CE, et al.
412 Postexposure Doxycycline to Prevent Bacterial Sexually Transmitted Infections. *N Engl J Med.*
413 2023;388(14):1296-306.

- 414 16. Luetkemeyer A, Donnell D, Cohen S, Dombrowski J, Grabow C, Brown C, et al. Sustained
415 Reduction of Bacterial STIs During the DoxyPEP Study Open-Label Extension Conference on
416 Retroviruses and Opportunistic Infections, Denver, Colorado2024 [updated 2024 March; cited 2024
417 01 May]. Available from: [https://www.croiconference.org/abstract/sustained-reduction-of-bacterial-](https://www.croiconference.org/abstract/sustained-reduction-of-bacterial-stis-during-the-doxy pep-study-open-label-extension/)
418 [stis-during-the-doxy pep-study-open-label-extension/](https://www.croiconference.org/abstract/sustained-reduction-of-bacterial-stis-during-the-doxy pep-study-open-label-extension/).
- 419 17. Sankaran M, Glidden D, Kohn R, Liebi C, Torres T, Buchbinder S, et al. Doxy-PEP Associated
420 With Declines in Chlamydia and Syphilis in MSM and Trans Women in San Francisco Conference on
421 Retroviruses and Opportunistic Infections, Denver, Colorado2024 [updated 2024 March; cited 2024
422 01 May]. Available from: [https://www.croiconference.org/abstract/doxy-pep-associated-with-](https://www.croiconference.org/abstract/doxy-pep-associated-with-declines-in-chlamydia-and-syphilis-in-msm-and-trans-women-in-san-francisco/)
423 [declines-in-chlamydia-and-syphilis-in-msm-and-trans-women-in-san-francisco/](https://www.croiconference.org/abstract/doxy-pep-associated-with-declines-in-chlamydia-and-syphilis-in-msm-and-trans-women-in-san-francisco/).
- 424 18. Leduc I, Connolly KL, Begum A, Underwood K, Darnell S, Shafer WM, et al. The serogroup B
425 meningococcal outer membrane vesicle-based vaccine 4CMenB induces cross-species protection
426 against *Neisseria gonorrhoeae*. *PLOS Pathogens*. 2020;16(12):e1008602.
- 427 19. Whittles LK, Didelot X, White PJ. Public health impact and cost-effectiveness of gonorrhoea
428 vaccination: an integrated transmission-dynamic health-economic modelling analysis. *Lancet Infect*
429 *Dis*. 2022;22(7):1030-41.
- 430 20. Ladhani SN, White PJ, Campbell H, Mandal S, Borrow R, Andrews N, et al. Use of a
431 meningococcal group B vaccine (4CMenB) in populations at high risk of gonorrhoea in the UK. *Lancet*
432 *Infect Dis*. 2024.
- 433 21. Abara WE, Bernstein KT, Lewis FMT, Schillinger JA, Feemster K, Pathela P, et al. Effectiveness
434 of a serogroup B outer membrane vesicle meningococcal vaccine against gonorrhoea: a
435 retrospective observational study. *The Lancet Infectious Diseases*. 2022;22(7):1021-9.
- 436 22. Petousis-Harris H, Paynter J, Morgan J, Saxton P, McArdle B, Goodyear-Smith F, Black S.
437 Effectiveness of a group B outer membrane vesicle meningococcal vaccine against gonorrhoea in
438 New Zealand: a retrospective case-control study. *The Lancet*. 2017;390(10102):1603-10.
- 439 23. Wang B, Giles L, Andraweera P, McMillan M, Almond S, Beazley R, et al. 4CMenB sustained
440 vaccine effectiveness against invasive meningococcal B disease and gonorrhoea at three years post
441 programme implementation. *Journal of Infection*. 2023;87(2):95-102.
- 442 24. Joint Committee on Vaccination and Immunisation. JCVI advice on the use of meningococcal
443 B vaccination for the prevention of gonorrhoea 2023 [cited 2024 04 April]. Available from:
444 [https://www.gov.uk/government/publications/meningococcal-b-vaccination-for-the-prevention-of-](https://www.gov.uk/government/publications/meningococcal-b-vaccination-for-the-prevention-of-gonorrhoea-jcvi-advice-10-november/jcvi-advice-on-the-use-of-meningococcal-b-vaccination-for-the-prevention-of-gonorrhoea)
445 [gonorrhoea-jcvi-advice-10-november/jcvi-advice-on-the-use-of-meningococcal-b-vaccination-for-](https://www.gov.uk/government/publications/meningococcal-b-vaccination-for-the-prevention-of-gonorrhoea-jcvi-advice-10-november/jcvi-advice-on-the-use-of-meningococcal-b-vaccination-for-the-prevention-of-gonorrhoea)
446 [the-prevention-of-gonorrhoea](https://www.gov.uk/government/publications/meningococcal-b-vaccination-for-the-prevention-of-gonorrhoea-jcvi-advice-10-november/jcvi-advice-on-the-use-of-meningococcal-b-vaccination-for-the-prevention-of-gonorrhoea).
- 447 25. Wayal S, Reid D, Weatherburn P, Blomquist P, Fabiane S, Hughes G, Mercer CH. Association
448 between knowledge, risk behaviours, and testing for sexually transmitted infections among men
449 who have sex with men: findings from a large online survey in the United Kingdom. *HIV medicine*.
450 2019;20(8):523-33.
- 451 26. Howarth A, Saunders J, Reid D, Kelly I, Wayal S, Weatherburn P, et al. 'Stay at home ...':
452 exploring the impact of the COVID-19 public health response on sexual behaviour and health service
453 use among men who have sex with men: findings from a large online survey in the UK. *Sexually*
454 *Transmitted Infections*. 2022;98(5):346.
- 455 27. Office for National Statistics. Personal well-being user guidance 2018 [Available from:
456 [https://www.ons.gov.uk/peoplepopulationandcommunity/wellbeing/methodologies/personalwellb](https://www.ons.gov.uk/peoplepopulationandcommunity/wellbeing/methodologies/personalwellbeingingsurveyuserguide)
457 [eingsurveyuserguide](https://www.ons.gov.uk/peoplepopulationandcommunity/wellbeing/methodologies/personalwellbeingingsurveyuserguide)].
- 458 28. Mercer CH, Tanton C, Prah P, Erens B, Sonnenberg P, Clifton S, et al. Changes in sexual
459 attitudes and lifestyles in Britain through the life course and over time: findings from the National
460 Surveys of Sexual Attitudes and Lifestyles (Natsal). *The Lancet*. 2013;382(9907):1781-94.
- 461 29. Hornuss D, Mathé P, Usadel S, Zimmermann S, Müller M, Rieg S. Already current practice? A
462 snapshot survey on doxycycline use for prevention of sexually transmitted infections in parts of the
463 German MSM community. *Infection*. 2023;51(6):1831-4.

- 464 30. European Centre for Disease Prevention and Control. EMIS-2017 The European Men-Who-
465 Have Sex-With-Men Internet Survey: Key findings from 50 countries 2019 [cited 2024 01 May].
466 Available from: [https://www.ecdc.europa.eu/sites/default/files/documents/European-MSM-](https://www.ecdc.europa.eu/sites/default/files/documents/European-MSM-internet-survey-2017-findings.pdf)
467 [internet-survey-2017-findings.pdf](https://www.ecdc.europa.eu/sites/default/files/documents/European-MSM-internet-survey-2017-findings.pdf).
- 468 31. Doran J, Weatherburn P, Hickson F, Marcus U, Reid D, Schmidt AJ. An update on the
469 performance of STI services for gay and bisexual men across European cities: results from the 2017
470 European MSM Internet Survey. *Sex Transm Infect.* 2021;97(3):201-8.
- 471 32. Chaintarli K, Ingle SM, Bhattacharya A, Ashiru-Oredope D, Oliver I, Gobin M. Impact of a
472 United Kingdom-wide campaign to tackle antimicrobial resistance on self-reported knowledge and
473 behaviour change. *BMC Public Health.* 2016;16:1-9.
- 474 33. King AJ, Bilardi JE, Maddaford K, Fairley CK, Chow EPF, Phillips TR. Sexual health clinic
475 attendees' views on antibiotic post-exposure prophylaxis and vaccinations for sexually transmitted
476 infections prevention: A qualitative study. *Preventive Medicine Reports.* 2024;38:102628.
- 477 34. Baldry G, Phillips D, Wilkie R, Checchi M, Folkard K, Simmons R, et al. Factors associated with
478 human papillomavirus, hepatitis A, hepatitis B and mpox vaccination uptake among gay, bisexual
479 and other men who have sex with men in the UK – findings from the large community-based RiSH-
480 Mpx survey. *medRxiv.* 2024:2024.03.08.24303981.
- 481 35. Fountain H, Migchelsen SJ, Charles H, Ram T, Fifer H, Mohammed H, Sinka K. Rebound of
482 Gonorrhoea after Lifting of COVID-19 Preventive Measures, England. *Emerg Infect Dis.*
483 2024;30(2):329-32.
- 484 36. Ogaz D, Enayat Q, Brown JRG, Phillips D, Wilkie R, Jayes D, et al. Mpx Diagnosis, Behavioral
485 Risk Modification, and Vaccination Uptake among Gay, Bisexual, and Other Men Who Have Sex with
486 Men, United Kingdom, 2022. *Emerg Infect Dis.* 2024;30(5).
- 487 37. Prah P, Hickson F, Bonell C, McDaid LM, Johnson AM, Wayal S, et al. Men who have sex with
488 men in Great Britain: comparing methods and estimates from probability and convenience sample
489 surveys. *Sex Transm Infect.* 2016;92(6):455-63.
- 490 38. Cabecinha M, Mercer CH, Gravningen K, Aicken C, Jones KG, Tanton C, et al. Finding sexual
491 partners online: prevalence and associations with sexual behaviour, STI diagnoses and other sexual
492 health outcomes in the British population. *Sex Transm Infect.* 2017;93(8):572-82.
- 493 39. Sullivan AK, Saunders J, Desai M, Cartier A, Mitchell HD, Jaffer S, et al. HIV pre-exposure
494 prophylaxis and its implementation in the PrEP Impact Trial in England: a pragmatic health
495 technology assessment. *Lancet HIV.* 2023;10(12):e790-e806.
- 496 40. PrEPster. 2024 [cited 2024 04 April]. Available from: <https://prepster.info/>.
- 497 41. I Want PrEP Now. 2024 [cited 2024 21 April]. Available from:
498 <https://www.iwantprepnw.co.uk/>.
- 499 42. Queer Health Info. doxyPEP 2024 [cited 2024 21 April]. Available from:
500 <https://www.queerhealth.info/projects/doxy pep>.
- 501 43. San Francisco Department of Public Health. Doxycycline Post-Exposure Prophylaxis Reduces
502 Incidence of Sexually Transmitted Infections 2022 [Available from: [https://www.sfdcp.org/wp-](https://www.sfdcp.org/wp-content/uploads/2022/10/Health-Update-Doxycycline-Post-Exposure-Prophylaxis-Reduces-Incidence-of-Sexually-Transmitted-Infections-SFDPH-FINAL-10.20.2022.pdf)
503 [content/uploads/2022/10/Health-Update-Doxycycline-Post-Exposure-Prophylaxis-Reduces-](https://www.sfdcp.org/wp-content/uploads/2022/10/Health-Update-Doxycycline-Post-Exposure-Prophylaxis-Reduces-Incidence-of-Sexually-Transmitted-Infections-SFDPH-FINAL-10.20.2022.pdf)
504 [Incidence-of-Sexually-Transmitted-Infections-SFDPH-FINAL-10.20.2022.pdf](https://www.sfdcp.org/wp-content/uploads/2022/10/Health-Update-Doxycycline-Post-Exposure-Prophylaxis-Reduces-Incidence-of-Sexually-Transmitted-Infections-SFDPH-FINAL-10.20.2022.pdf)].

505

506 **Table 1. RiiSH 2023 participant characteristics (n=1,106)**

	% (No.)
All RiiSH 2023 participants	100% (1,106)
Recruitment site	
Grindr	50% (553)
Instagram	23% (253)
Facebook	19% (213)
Twitter	1% (8)
Community-cascaded link	7% (79)
Sociodemographic characteristics	
Age at survey completion (interquartile range)	44 (34-54)
Age at survey completion (standard deviation)	44.1 (12.7)
Age-group (3 categories)	
16-29	14% (151)
30-44	38% (416)
45 and over	49% (539)
Gender identity and sex at birth	
All other gender identity groups	5% (55)
Cisgender male	95% (1,051)
Sexual orientation	
Gay/homosexual	82% (910)
Bisexual‡	18% (196)
Ethnic group	
White	89% (984)
Black	2% (17)
Asian	5% (56)
Mixed or other	4% (49)
Country of birth	
Outside of the UK	22% (246)
UK	78% (860)
Nation of residence	
Scotland, Wales, or N Ireland	15% (165)
England	85% (941)
Employment	
Not employed	22% (238)
Current employment (full-time, part-time, self-employed)	78% (868)
Educational qualifications	
Below degree-level	38% (415)
Degree-level or higher	62% (691)
Lives with partner(s)	
No	63% (693)
Yes	37% (413)
Comfortable financial situation	
No	59% (652)
Yes (top two quartiles)§	41% (454)
Clinical and behavioural characteristics	
HIV status and HIV-PrEP use history	


HIV negative/unknown - Never used HIV-PrEP	39% (433)
HIV negative/unknown - No HIV-PrEP use since August 2023	9% (105)
HIV negative/unknown - HIV-PrEP use since August 2023	38% (425)
PLWHIV	13% (143)
Recreational drug use associated with chemsex in the last year	
No	93% (1,030)
Yes‡	7% (76)
Bacterial STI diagnosis since August 2023	
No	91% (1,010)
Yes	9% (96)
Tried to get an STI test since August 2023	
No	48% (532)
Yes, able to get a STI test	44% (489)
Yes, unable to get a STI test	8% (85)
SHS visit since December 2022 (last year)	
No	42% (470)
Yes	58% (636)
Mpox vaccination history (≥1 dose)	
No	58% (636)
Yes	42% (470)
Partnerships since August 2023	
Any new male physical sex partner(s)	
No new partners	32% (351)
1 or more new partners	68% (755)
Met male physical sex partner(s) at SOP venue, sex party, or cruising location	
No	85% (945)
Yes	15% (161)
Number of male physical sex partner(s)	
No sex or only virtual sex	12% (138)
1 partner	20% (226)
2-4 partners	25% (277)
5-9 partners	18% (195)
10 or more partners	24% (270)
Number of male condomless anal sex (CAS) partner(s)	
No known CAS partners	35% (383)
1 CAS partner	24% (270)
2-4 CAS partners	20% (222)
5 or more CAS partners	21% (231)
Markers of sexual risk in the last 3 months (composite)¶	
No	67% (745)
Yes	33% (361)
Personal well-being measures	
Low life satisfaction	
No	78% (862)
Yes	22% (242)
Not specified	<1% (2)
Low life worthwhileness	
No	80% (887)
Yes	20% (217)
Not specified	<1% (2)

Low happiness (yesterday)	
No	77% (853)
Yes	23% (251)
Not specified	<1% (2)
High anxiety (yesterday)	
No	63% (695)
Yes	37% (409)
Not specified	<1% (2)
Sexual satisfaction	
"I feel satisfied with my sex life" ^{††}	
Disagree/do not agree nor disagree	58% (646)
Agree/strongly agree	42% (460)
Intention to use doxyPEP*	
Very unlikely	10% (112)
Somewhat unlikely	10% (110)
Somewhat likely	23% (251)
Very likely	51% (568)
Don't know	6% (65)
Intention to use 4CMenB*	
Very unlikely	7% (78)
Somewhat unlikely	6% (63)
Somewhat likely	19% (210)
Very likely	64% (713)
Don't know	4% (42)
Ever used antibiotic PEP*	
No	1,109 (92%)
Yes ^{‡‡}	87 (8%)
<p>[‡]Includes those identifying as bisexual, straight, or another way. [§]Top two quartiles ("I am comfortable"/"I am very comfortable" from the question, "How would you best describe your current financial situation".</p> <p>[‡]Includes crystal methamphetamine, mephedrone or gamma-hydroxybutyrate/gamma-butyrolactone.</p> <p>[¶]Includes reporting of: ≥5 condomless anal sex partners, bacterial STI diagnosis, chemsex, and/or meeting partners at sex-on-premises venue, sex party, or cruising location in the last three months (i.e., since August 2023). ^{††}Based on participant response to statement. *See Appendix Table I for survey questions and preambles. ^{‡‡}Ever reporting the use of antibiotics after sex for STI prevention. PEP=post-exposure prophylaxis. doxyPEP=doxycycline post-exposure prophylaxis. HIV-PrEP=HIV pre-exposure prophylaxis. PLWHIV=people living with HIV. STI=sexually transmitted infection. SHS=sexual health service. SOP=sex-on-premises. CAS=condomless anal sex. RiiSH='Reducing inequalities in Sexual Health'.</p>	

507

508

509 **Figure 1: Knowledge and uptake of antibiotic post-exposure prophylaxis (PEP) among RiiSH 2023 participants (n=1,106)**



510

511 *See Appendix I for survey questions and preambles; report of knowledge and use of antibiotics after sex for STI prevention (i.e., antibiotic PEP). PEP=post-
512 exposure prophylaxis.

513

514 **Table 2. Correlates of ever reporting antibiotic post-exposure prophylaxis (PEP) use for STI prevention among an online community sample of**
 515 **GBMSM taking part in the RiiSH 2023 survey**

	Ever used antibiotic PEP ^{†‡}					
	row % (No.)	uOR (95% CI)	p-value	aOR (95% CI)**	p-value	
Total	8% (87)					
Sociodemographic characteristics						
Age at survey completion (interquartile range)	45 (37-56)					
Age at survey completion (standard deviation)	45.7 (10.7)					
Age-group (3 categories)						
16-29	4% (6)	0.43 (0.18-1.03)		0.53 (0.22-1.29)		
30-44	8% (34)	0.93 (0.59-1.48)		0.91 (0.57-1.48)		
45 and over	9% (47)	1.00 (base)	0.15	1.00 (base)	0.33	
Gender identity and sex at birth						
All other gender identity groups	7% (4)	0.91 (0.32-2.59)		..		
Cisgender male	8% (83)	1.00 (base)	0.87	..		
Sexual orientation						
Gay/homosexual	8% (77)	1.00 (base)		..		
Bisexual [‡]	5% (10)	0.58 (0.30-1.15)	0.11	..		
Ethnic group (2 categories)						
All other ethnic groups	11% (13)	1.47 (0.79-2.73)		..		
White	8% (74)	1.00 (base)	0.22	..		
Country of birth						
Outside of the UK	11% (28)	1.74 (1.09-2.80)		1.65 (1.01-2.70)		
UK	7% (59)	1.00 (base)	0.020	1.00 (base)	0.051	
Nation of residence						
Scotland, Wales, or N Ireland	6% (10)	0.72 (0.37-1.43)		..		
England	8% (77)	1.00 (base)	0.35	..		
Employment						
Not employed	6% (15)	0.74 (0.42-1.32)		..		

Current employment (full-time, part-time, self-employed)	8% (72)		1.00 (base)	0.31		..
Educational qualifications						
Below degree-level	5% (21)		0.50 (0.30-0.84)			0.58 (0.34-0.97)
Degree-level or higher	10% (66)		1.00 (base)	0.007		1.00 (base) 0.030
Lives with partner(s)						
No	8% (58)		1.21 (0.76-1.92)			..
Yes	7% (29)		1.00 (base)	0.42		..
Comfortable financial situation						
No	7% (48)		0.85 (0.54-1.31)			..
Yes (top two quartiles)§	9% (39)		1.00 (base)	0.46		..
Clinical and behavioural characteristics						
HIV status and HIV-PrEP use history						
HIV negative/unknown - No HIV-PrEP use since August 2023	2% (12)		1.00 (base)			1.00 (base)
HIV negative/unknown - HIV-PrEP use since August 2023	12% (53)		6.25 (3.29-11.8)			4.54 (2.33-8.85)
PLWHIV	15% (22)		7.97 (3.84-16.5)	<0.001		6.00 (2.81-12.8) <0.001
Recreational drug use associated with chemsex in the last year						
No	7% (67)		1.00 (base)			..
Yes‡	26% (20)		5.13 (2.91-9.05)	<0.001		..
Bacterial STI diagnosis since August 2023						
No	7% (69)		1.00 (base)			..
Yes	19% (18)		3.15 (1.78-5.55)	<0.001		..
SHS visit since December 2022 (last year)						
No	5% (23)		1.00 (base)			1.00 (base)
Yes	10% (64)		2.17 (1.33-3.58)	0.001		1.47 (0.87-2.49) 0.14
Mpox vaccination history (≥1 dose)						
No	4% (28)		1.00 (base)			1.00 (base)
Yes	13% (59)		3.12 (1.95-4.97)	<0.001		2.24 (1.37-3.66) 0.001
"Very likely" to consider 4CMenB uptake (i.e. 4CMenB ITU)						
No	4% (17)		1.00 (base)			1.00 (base)
Yes	10% (70)		2.41 (1.40-4.15)	0.001		1.97 (1.12-3.46) 0.013
Partnerships since August 2023						
Any new male physical sex partner(s)						

No new partners	5% (19)		0.58 (0.34-0.98)			..
1 or more new partners	9% (68)		1.00 (base)	0.039		..
Met male physical sex partner(s) at SOP venue, sex party, or cruising location						
No	6% (60)		1.00 (base)			..
Yes	17% (27)		2.97 (1.82-4.85)	<0.001		..
Five or more male condomless anal sex partners						
No	5% (42)		1.00 (base)			..
Yes	19% (45)		4.80 (3.06-7.52)	<0.001		..
Markers of sexual risk in the last 3 months (composite)*						
No	5% (37)		1.00 (base)			1.00 (base)
Yes	14% (65)		3.08 (1.97-4.80)	<0.001		2.84 (1.81-4.47) <0.001
Personal well-being measures						
Low life satisfaction						
No	8% (68)		1.00 (base)			..
Yes	8% (19)		0.99 (0.59-1.69)	0.98		..
Not specified	0% (0)					
Low life worthwhileness						
No	7% (66)		1.00 (base)			..
Yes	10% (21)		1.33 (0.80-2.23)	0.27		..
Not specified	0% (0)					
Low happiness (yesterday)						
No	8% (67)		1.00 (base)			..
Yes	8% (20)		1.02 (0.60-1.71)	0.95		..
Not specified	0% (0)					
High anxiety (yesterday)						
No	9% (61)		1.00 (base)			..
Yes	6% (26)		0.71 (0.44-1.14)	0.15		..
Not specified	0% (0)					
Sexual satisfaction						
"I feel satisfied with my sex life"††						
Disagree/do not agree nor disagree	6% (41)		1.00 (base)			1.00 (base)
Agree/strongly agree	10% (46)		1.64 (1.06-2.54)	0.027		1.36 (0.86-2.13) 0.19

<p>‡Includes those identifying as bisexual, straight, or another way. §Top two quartiles ("I am comfortable"/"I am very comfortable" from the question, "How would you best describe your current financial situation". †Includes crystal methamphetamine, mephedrone or gamma-hydroxybutyrate/gamma-butyrolactone. ¶Includes reporting of: ≥5 condomless anal sex partners, bacterial STI diagnosis, chemsex, and/or meeting partners at sex-on-premises venue, sex party, or cruising location in the last three months (i.e., since August 2023). ††Based on participant response to statement. *See Appendix Table I for survey questions and preambles. ‡‡Ever reporting the use of antibiotics after sex for STI prevention (i.e., antibiotic PEP). **Adjusted for age-group (a priori selection), country of birth, educational qualifications, markers of sexual risk. uOR=unadjusted odds ratio. aOR=adjusted odds ratio. PEP=post-exposure prophylaxis. HIV-PrEP=HIV pre-exposure prophylaxis. PLWHIV=people living with HIV. STI=sexually transmitted infection. SHS=sexual health service. SOP=sex-on-premises. CAS=condomless anal sex. RiiSH='Reducing inequalities in Sexual Health'.</p>						

516

517

518 **Table 3. Correlates of reporting intention to use doxyPEP (doxyPEP ITU) among an online community sample of GBMSM taking part in the RiSH**
 519 **2023 survey**

	Reporting intention to use doxyPEP (i.e. doxyPEP ITU) ^{‡‡}				
	row % (No.)	uOR (95% CI)	p-value	aOR (95% CI)**	p-value
Total	51% (568)				
Sociodemographic characteristics					
Age at survey completion (interquartile range)	44 (35-54)				
Age at survey completion (standard deviation)	44.4 (12.3)				
Age-group (3 categories)					
16-29	42% (63)	0.66 (0.46-0.95)		0.71 (0.49-1.03)	
30-44	54% (225)	1.09 (0.84-1.41)		1.13 (0.87-1.46)	
45 and over	52% (280)	1.00 (base)	0.031	1.00 (base)	0.059
Gender identity and sex at birth					
All other gender identity groups	45% (25)	0.78 (0.45-1.34)		..	
Cisgender male	52% (543)	1.00 (base)	0.37	..	
Sexual orientation					
Gay/homosexual	51% (467)	1.00 (base)		..	
Bisexual [‡]	52% (101)	1.01 (0.74-1.37)	0.96	..	
Ethnic group (2 categories)					
All other ethnic groups	53% (65)	1.09 (0.75-1.59)		..	
White	51% (503)	1.00 (base)	0.65	..	
Country of birth					
Outside of the UK	54% (134)	1.17 (0.88-1.56)		..	
UK	50% (434)	1.00 (base)	0.27	..	
Nation of residence					
Scotland, Wales, or N Ireland	52% (85)	1.01 (0.72-1.40)		..	
England	51% (483)	1.00 (base)	0.96	..	
Employment					
Not employed	47% (113)	0.82 (0.62-1.09)		..	
Current employment (full-time, part-time, self-employed)	52% (455)	1.00 (base)	0.18	..	

Educational qualifications						
Below degree-level	52% (215)	1.03 (0.81-1.31)				..
Degree-level or higher	51% (353)	1.00 (base)	0.82			..
Lives with partner(s)						
No	49% (343)	0.82 (0.64-1.05)				..
Yes	54% (225)	1.00 (base)	0.11			..
Comfortable financial situation						
No	50% (328)	0.90 (0.71-1.15)				..
Yes (top two quartiles)§	53% (240)	1.00 (base)	0.40			..
Clinical and behavioural characteristics						
HIV status and HIV-PrEP use history						
HIV negative/unknown - No HIV-PrEP use since August 2023	45% (242)	1.00 (base)				1.00 (base)
HIV negative/unknown - HIV-PrEP use since August 2023	56% (238)	1.56 (1.21-2.01)				1.40 (1.17-1.84)
PLWHIV	21% (88)	1.96 (1.34-2.85)	<0.001			1.74 (1.28-2.57) 0.006
Recreational drug use associated with chemsex in the last year						
No	51% (524)	1.00 (base)				..
Yes‡	58% (44)	1.33 (0.83-2.13)	0.24			..
Bacterial STI diagnosis since August 2023						
No	50% (501)	1.00 (base)				..
Yes	70% (67)	2.35 (1.49-3.69)	<0.001			..
SHS visit since December 2022 (last year)						
No	43% (202)	1.00 (base)				1.00 (base)
Yes	58% (366)	1.80 (1.41-2.29)	<0.001			1.66 (1.29-2.14) <0.001
Mpox vaccination history (≥1 dose)						
No	48% (303)	1.00 (base)				1.00 (base)
Yes	56% (265)	1.42 (1.12-1.81)	0.004			1.28 (1.10-1.64) 0.054
"Very likely" to consider 4CMenB uptake (i.e. 4CMenB ITU)						
No	21% (81)	1.00 (base)				1.00 (base)
Yes	68% (487)	8.30 (6.21-11.1)	<0.001			8.82 (6.62-11.93) <0.001
Partnerships since August 2023						
Any new male physical sex partner(s)						
No new partners	46% (162)	0.74 (0.57-0.95)				..

1 or more new partners	54% (406)	1.00 (base)	0.018	..	
Met male physical sex partner(s) at SOP venue, sex party, or cruising location					
No	51% (481)	1.00 (base)		..	
Yes	54% (87)	1.13 (0.81-1.59)	0.46	..	
Five or more male condomless anal sex partners					
No	48% (416)	1.00 (base)		..	
Yes	66% (152)	2.12 (1.57-2.87)	<0.001	..	
Markers of sexual risk in the last 3 months (composite) ^{¶¶}					
No	48% (357)	1.00 (base)		1.00 (base)	
Yes	58% (211)	1.53 (1.19-1.97)	0.001	1.50 (1.16-1.94)	<0.001
Personal well-being measures					
Low life satisfaction					
No	52% (445)	1.00 (base)		..	
Yes	50% (121)	0.94 (0.70-1.25)	0.35	..	
Not specified	100% (2)				
Low life worthwhileness					
No	51% (453)	1.00 (base)		..	
Yes	52% (113)	1.04 (0.77-1.40)	0.37	..	
Not specified	100% (2)				
Low happiness (yesterday)					
No	51% (435)	1.00 (base)		..	
Yes	52% (131)	1.05 (0.79-1.39)	0.37	..	
Not specified	100% (2)				
High anxiety (yesterday)					
No	54% (372)	1.00		1.00 (1.00)	
Yes	47% (194)	0.78 (0.61-1.00)	0.057	0.77 (0.80-0.99)	0.040
Not specified	100% (2)				
Sexual satisfaction					
"I feel satisfied with my sex life" ^{††}					
Disagree/do not agree nor disagree	51% (327)	1.00		..	
Agree/strongly agree	52% (241)	1.07 (0.88-1.20)	0.56	..	

‡Includes those identifying as bisexual, straight, or another way. §Top two quartiles ("I am comfortable"/"I am very comfortable" from the question, "How would you best describe your current financial situation". †Includes crystal methamphetamine, mephedrone or gamma-hydroxybutyrate/gamma-butyrolactone. ¶Includes reporting of: ≥5 condomless anal sex partners, bacterial STI diagnosis, chemsex, and/or meeting partners at sex-on-premises venue, sex party, or cruising location in the last three months (i.e., since August 2023). ††Based on participant response to statement. *See Appendix Table I for survey questions and preambles. ‡‡Participants 'very likely' to consider doxyPEP uptake (See Appendix Table 1 for survey questions and preambles). **Adjusted for age-group (a priori selection), markers of sexual risk. uOR=unadjusted odds ratio. aOR=adjusted odds ratio. PEP=post-exposure prophylaxis. doxyPEP=doxycycline post-exposure prophylaxis. HIV-PrEP=HIV pre-exposure prophylaxis. PLWHIV=people living with HIV. STI=sexually transmitted infection. SHS=sexual health service. SOP=sex-on-premises. CAS=condomless anal sex. RiiSH='Reducing inequalities in Sexual Health'.

520

521

522 **Table 4. Correlates of reporting intention to use 4CMenB (4CMenB ITU) among an online community sample of GBMSM taking part in the RiISH**
 523 **2023 survey**

	Reporting intention to use 4CMenB (i.e. 4CMenB ITU)¶¶				
	row % (No.)	uOR (95% CI)	p-value	aOR (95% CI)**	p-value
Total	64% (713)				
Sociodemographic characteristics					
Age at survey completion (interquartile range)	42 (34-52)				
Age at survey completion (standard deviation)	42.8 (12.2)				
Age-group (3 categories)					
16-29	69% (104)	1.60 (1.09-2.35)		2.16 (1.44-3.25)	
30-44	71% (296)	1.78 (1.36-2.34)		1.84 (1.39-2.45)	
45 and over	58% (313)	1.00 (base)	<0.001	1.00 (base)	<0.001
Gender identity and sex at birth					
All other gender identity groups	67% (37)	1.14 (0.64-2.03)		..	
Cisgender male	64% (676)	1.00 (base)	0.66	..	
Sexual orientation					
Gay/homosexual	66% (605)	1.00 (base)		1.00 (base)	
Bisexual‡	55% (108)	0.62 (0.45-0.85)	0.003	0.62 (0.45-0.86)	0.0044
Ethnic group (2 categories)					
All other ethnic groups	66% (80)	1.06 (0.71-1.57)		..	
White	64% (633)	1.00 (base)	0.79	..	
Country of birth					
Outside of the UK	69% (170)	1.31 (0.96-1.77)		..	
UK	63% (543)	1.00 (base)	0.085	..	
Nation of residence					
Scotland, Wales, or N Ireland	65% (107)	1.02 (0.72-1.44)		..	
England	64% (606)	1.00 (base)	0.91	..	
Employment					

Not employed	59% (140)	0.74 (0.55-0.99)		0.85 (0.62-1.15)	
Current employment (full-time, part-time, self-employed)	66% (573)	1.00 (base)	0.040	1.00 (base)	0.29
Educational qualifications					
Below degree-level	55% (230)	0.54 (0.42-0.69)		0.57 (0.44-0.73)	
Degree-level or higher	70% (483)	1.00 (base)	<0.001	1.00 (base)	<0.001
Lives with partner(s)					
No	65% (448)	1.02 (0.79-1.32)		..	
Yes	64% (265)	1.00 (base)	0.87	..	
Comfortable financial situation					
No	63% (411)	0.86 (0.67-1.10)		..	
Yes (top two quartiles)§	67% (302)	1.00 (base)	0.23	..	
Clinical and behavioural characteristics					
HIV status and HIV-PrEP use history					
HIV negative/unknown - No HIV-PrEP use since August 2023	54% (289)	1.00 (base)		1.00 (base)	
HIV negative/unknown - HIV-PrEP use since August 2023	76% (323)	2.73 (2.06-3.61)		2.26 (1.67-3.05)	
PLWHIV	71% (101)	2.07 (1.39-3.08)	<0.001	1.96 (1.28-2.99)	<0.001
Recreational drug use associated with chemsex in the last year					
No	63% (652)	1.00 (base)		..	
Yes‡	80% (61)	2.36 (1.32-4.21)	0.003	..	
Bacterial STI diagnosis since August 2023					
No	63% (635)	1.00 (base)		..	
Yes	81% (78)	2.56 (1.51-4.34)	<0.001	..	
SHS visit since December 2022 (last year)					
No	50% (236)	1.00 (base)		1.00 (base)	
Yes	75% (477)	2.97 (2.30-3.84)	<0.001	2.45 (1.87-3.21)	<0.001
Mpox vaccination history (≥1 dose)					
No	55% (347)	1.00 (base)		1.00 (base)	
Yes	78% (366)	2.93 (2.24-3.83)	<0.001	2.38 (1.79-3.16)	<0.001
"Very likely" to consider doxyPEP uptake (i.e. doxyPEP ITU)					
No	32% (226)	1.00 (base)		1.00 (base)	
Yes	68% (487)	8.30 (6.21-11.10)	<0.001	10.1 (7.33-13.8)	<0.001
Ever used antibiotic PEP‡‡					
No	63% (643)	1.00 (base)		1.00 (base)	

Yes	80% (70)	2.41 (1.40-4.15)	<0.001	1.99 (1.13-3.50)	0.013
Partnerships since August 2023					
Any new male physical sex partner(s)					
No new partners	54% (188)	0.51 (0.39-0.66)		..	
1 or more new partners	70% (525)	1.00 (base)	<0.001	..	
Met male physical sex partner(s) at SOP venue, sex party, or cruising location					
No	54% (188)	1.00 (base)		..	
Yes	70% (525)	1.26 (0.88-1.81)	<0.001	..	
Five or more male condomless anal sex partners					
No	60% (524)	1.00 (base)		..	
Yes	82% (189)	3.01 (2.10-4.32)	<0.001	..	
Markers of sexual risk in the last 3 months (composite)*					
No	59% (443)	1.00 (base)		1.00 (base)	
Yes	75% (270)	2.02 (1.53-2.67)	<0.001	2.09 (1.56-2.79)	<0.001
Personal well-being measures					
Low life satisfaction					
No	65% (560)	1.00 (base)		..	
Yes	63% (152)	0.91 (0.68-1.22)	0.75	..	
Not specified	50% (1)				
Low life worthwhileness					
No	65% (579)	1.00 (base)		..	
Yes	61% (133)	0.84 (0.62-1.14)	0.50	..	
Not specified	50% (1)				
Low happiness (yesterday)					
No	65% (551)	1.00 (base)		..	
Yes	64% (161)	0.98 (0.73-1.32)	0.90	..	
Not specified	50% (1)				
High anxiety (yesterday)					
No	64% (442)	1.00 (base)		..	
Yes	66% (270)	1.11 (0.86-1.44)	0.66	..	
Not specified	50% (1)				

Sexual satisfaction						
"I feel satisfied with my sex life" ^{††}						
Disagree/do not agree nor disagree	63% (404)		1.00 (base)			..
Agree/strongly agree	67% (309)		1.23 (0.95-1.58)	0.11		..

[‡]Includes those identifying as bisexual, straight, or another way. [§]Top two quartiles ("I am comfortable"/"I am very comfortable" from the question, "How would you best describe your current financial situation". [‡]Includes crystal methamphetamine, mephedrone or gamma-hydroxybutyrate/gamma-butyrolactone. ^{‡‡}Ever reporting the use of antibiotics after sex for STI prevention (i.e., antibiotic PEP). [¶]Includes reporting of: ≥ 5 condomless anal sex partners, bacterial STI diagnosis, chemsex, and/or meeting partners at sex-on-premises venue, sex party, or cruising location in the last three months (i.e., since August 2023). ^{††}Based on participant response to statement. *See Appendix Table I for survey questions and preambles. ^{¶¶}Participants 'very likely' to consider 4CMenB uptake (See Appendix Table 1 for survey questions and preambles). **Adjusted for age-group (a priori selection), sexual orientation, employment status, educational qualifications, markers of sexual risk. uOR=unadjusted odds ratio. aOR=adjusted odds ratio. PEP=post-exposure prophylaxis. doxyPEP=doxycycline post-exposure prophylaxis. HIV-PrEP=HIV pre-exposure prophylaxis. PLWHIV=people living with HIV. STI=sexually transmitted infection. SHS=sexual health service. SOP=sex-on-premises. CAS=condomless anal sex. RiSH='Reducing inequalities in Sexual Health'.